Mazindol ADHD Treatment Plasma Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ADHD, particularly psychostimulants, have limitations such as short plasma half-lives leading to withdrawal effects, toxic risks, and inadequate management of symptoms like insomnia and inattention, and are not suitable for children due to administration challenges.
Innovation Solution
Mazindol, a non-amphetamine compound with a long plasma half-life and low toxic potential, is used as a monotherapy or in combination with psychostimulants, offering improved symptom management without withdrawal effects and toxic risks, and is administered once daily, suitable for children.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psychostimulants (methylphenidate, amphetamines) are used to treat ADHD, then motor hyperactivity improvement is significant, but plasma half-life is short causing withdrawal effects and symptom rebound
Solution Approach 1:
The patent changes the pharmacokinetic parameter of plasma half-life by selecting mazindol (with half-life >24 hours) instead of conventional psychostimulants (with short half-lives). This parameter change eliminates the withdrawal effect and symptom rebound while maintaining reliable symptom control throughout the day.
2Reliability
If psychostimulants are used to treat ADHD, then arousing effect is achieved, but toxic risk increases
Solution Approach 1:
The patent changes the safety parameter by selecting mazindol, which has demonstrated low toxic potential in clinical studies, replacing conventional psychostimulants that carry higher toxic risks including cardiovascular effects and potential for misuse.
3Reliability
If conventional medicinal products are administered to children with ADHD, then treatment is provided, but administration difficulties arise due to tablet size and multi-day regimens
Solution Approach 1:
The patent changes the dosing frequency parameter from multi-day administration to once-daily administration, and selects tablet sizes appropriate for pediatric patients. This makes the treatment regimen practical for children while maintaining comprehensive symptom coverage.
4Reliability
If psychostimulants are used to treat ADHD, then daytime alertness is improved, but nocturnal motor agitation increases causing insomnia
Solution Approach 1:
The patent changes the pharmacokinetic parameter of plasma half-life to >24 hours, which allows for sustained daytime alertness while the drug's prolonged presence in the system prevents the sharp decline that triggers nocturnal motor agitation and insomnia associated with shorter-acting psychostimulants.
Data Source
AI summary
The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.